Shares of Cadila Healthcare added 2 percent intraday Tuesday as it has received USFDA nod for Tizanidine tablets.
Zydus Cadila has received a final approval from the USFDA to market Tizanidine tablets USP in the strength of 2 mg and 4 mg
The drug is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury and works by helping to relax the muscles.
It will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.
The group has now more than 180 approvals and has to filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.